Isomorphic Labs announces Series B investment round - Isomorphic Labs
Our Team
Our Tech
Partnerships
Careers
Life At Iso
Work With Us
Job Openings
News
Our Team
Our Tech
Partnerships
Careers
Life at Iso
Work with Us
Job Openings
News
Announcement
Isomorphic Labs announces Series B investment round
May 12, 2026
min Read
min Read
min Read
min Read
min listen
min watch
Copy url
Table of Contents
Listen:
Spotify
Apple Podcasts
Isomorphic Labs announces it has raised $2.1 Billion in Series B funding. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base.
Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine (IsoDDE) to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities.
Read more in the news release below.
‍
Isomorphic Labs announces
$2.1 Billion funding to power its world-leading AI drug design engine, scale its business globally and progress its drug candidate pipeline.
Read more
Follow us
Linkedin
X
Related
© 2026 ISOMORPHIC LABS
Home
Life at Iso
Our Team
Work With Us
Our Tech
Job Openings
Partnerships
News
Linkedin
X
CONTACT US
press@isomorphiclabs.com
partnering@isomorphiclabs.com
connecting@isomorphiclabs.com
INFO
Privacy Notice
Cookie Notice
Terms & Conditions
Supplier Code of Conduct
Manage Cookies